Buy & Sell ProShares UltraShort Bloomberg Natural Gas ETF (KOLD) – ProShares UltraShort Bloomberg Natural Gas ETF Price Today
Key Stats
- -Market Cap
- Leveraged / InverseSector
- -24.78%3M Drawdown
- -Enterprise Value
- -Dividend Yield
- 100% Buy | 0% SellTrading Activity
- 3 daysTypical Hold Time
Over the past 52 weeks, ProShares UltraShort Bloomberg Natural Gas ETF has traded between a low of $13.58 and a high of $49.39, highlighting its annual price range. Over the past three months, ProShares UltraShort Bloomberg Natural Gas ETF has recorded a drawdown of -24.78%, reflecting recent price volatility. On average, investors hold ProShares UltraShort Bloomberg Natural Gas ETF for approximately 3 days, indicating typical investor behavior on the platform.
About ProShares UltraShort Bloomberg Natural Gas ETF
KOLD is an inverse leveraged ETF that seeks to provide two times (2x) the inverse daily performance of the Bloomberg Natural Gas Subindex. It is designed for investors looking to profit from falling natural gas prices.
Most Recent News
Boston Scientific invests $1.5B for stake in MiRus, targeting advanced aortic stenosis treatment.
Boston Scientific has invested $1.5 billion to acquire about a 34% stake in MiRus, gaining exclusive rights to its investigational transcatheter aortic valve replacement (TAVR) system designed for severe aortic stenosis. The SIEGEL valve features a n...
Elliott sees hidden value in Bio-Rad via $5B Sartorius stake amid share price slump
Activist investor Elliott Investment Management has taken a significant stake in Bio-Rad Laboratories, which develops medical instruments and software. Bio-Rad's founding family retains majority voting control, complicating activist efforts. Elliott ...
Regeneron's melanoma trial fails, stock drops over 10%, investors urged to explore legal options.
Regeneron Pharmaceuticals announced that its Phase 3 melanoma trial combining fianlimab and Libtayo did not meet the primary endpoint against Keytruda, causing the stock to fall more than 10%. Prior optimism from company executives about the trial's ...
